Position of the Transparency Council – Trodelvy (sacituzumab govitecan)
At its meeting on 28 October 2024,, the Transparency Council adopted position No. 113/2024 on the evaluation of the drug Trodelvy (sacituzumab govitecan) under the drug program B.9.FM. “Treatment of patients with breast cancer (ICD-10: C50)”